{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:56:15Z","timestamp":1793361375339,"version":"4.5.0"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Recent studies on renin-angiotensin system (RAS) inhibitors have reported a reduced risk of Alzheimer\u2019s disease (AD). Nevertheless, the effect of RAS inhibitor type and blood\u2013brain barrier (BBB) permeability on the risk of AD is still unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To assess the effects of RAS inhibitors on the risk of AD based on the type and BBB permeability and investigate the cumulative duration-response relationship.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a population-based retrospective cohort study using the Korean Health Insurance Review and Assessment database records from 2008 to 2019. The data of patients diagnosed with ischemic heart disease between January 2009 and June 2009 were identified for inclusion in the analyses. Propensity score matching was used to balance RAS inhibitor users with non-users. The association between the use of RAS inhibitors and incident AD was evaluated using a multivariate Cox proportional hazard regression model. The results are presented in adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 57,420 matched individuals, 7,303 developed AD within the follow-up period. While the use of angiotensin-converting enzyme inhibitors (ACEIs) was not significantly associated with AD risk, the use of angiotensin II receptor blockers (ARBs) showed a significant association with reduced risk of incident AD (aHR\u2009=\u20090.94; 95% CI\u2009=\u20090.90\u20130.99). Furthermore, the use of BBB-crossing ARBs was associated with a lower risk of AD (aHR\u2009=\u20090.83; 95% CI\u2009=\u20090.78\u20130.88) with a cumulative duration-response relationship. A higher cumulative dose or duration of BBB-crossing ARBs was associated with a gradual decrease in AD risk (<jats:italic>P for trend\u2009&amp;lt;\u20090.001<\/jats:italic>). No significant association between the use of ACEIs and the risk of AD was observed regardless of BBB permeability.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Long-term use of BBB-crossing ARBs significantly reduced the risk of AD development. The finding may provide valuable insight into disease-modifying drug options for preventing AD in patients with cardiovascular diseases.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnagi.2023.1137197","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T06:06:10Z","timestamp":1678082770000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":47,"title":["Neuroprotective effect of angiotensin II receptor blockers on the risk of incident Alzheimer\u2019s disease: A nationwide population-based cohort study"],"prefix":"10.3389","volume":"15","author":[{"given":"Hyun Woo","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngkwon","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youjin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Seok","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Mi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.sjbs.2020.01.026","article-title":"Role of brain renin angiotensin system in neurodegeneration: an update","volume":"27","author":"Abiodun","year":"2020","journal-title":"Saudi J. Biol. Sci."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jsps.2020.03.009","article-title":"Possible combined effect of perindopril and Azilsartan in an experimental model of dementia in rats","volume":"28","author":"Alzahrani","year":"2020","journal-title":"Saudi Pharm. J."},{"key":"ref3","volume-title":"World Alzheimer Report 2019: Attitudes to Dementia","year":"2019"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jgs.15767","article-title":"American Geriatrics Society 2019 updated Ags beers criteria\u00ae for potentially inappropriate medication use in older adults","volume":"67","year":"2019","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.mcna.2018.10.009","article-title":"The Alzheimer's disease clinical Spectrum: diagnosis and management","volume":"103","author":"Atri","year":"2019","journal-title":"Med. Clin. North Am."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm. Stat."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/med.21434","article-title":"Drugs in clinical trials for Alzheimer's disease: the major trends","volume":"37","author":"Bachurin","year":"2017","journal-title":"Med. Res. Rev."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S0140-6736(10)61349-9","article-title":"Alzheimer's disease","volume":"377","author":"Ballard","year":"2011","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e0206705","DOI":"10.1371\/journal.pone.0206705","article-title":"The association of multiple anti-hypertensive medication classes with Alzheimer's disease incidence across sex, race, and ethnicity","volume":"13","author":"Barthold","year":"2018","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","article-title":"Identification of Telmisartan as a unique angiotensin ii receptor antagonist with selective Ppargamma-modulating activity","volume":"43","author":"Benson","year":"2004","journal-title":"Hypertension"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1177\/0091270006292126","article-title":"The anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity","volume":"46","author":"Carnahan","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1097\/HJH.0000000000000086","article-title":"Angiotension receptor blockers reduce the risk of dementia","volume":"32","author":"Chiu","year":"2014","journal-title":"J. Hypertens."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1016\/j.neurobiolaging.2014.05.002","article-title":"Use of diuretics is associated with reduced risk of Alzheimer's disease: the Cache County study","volume":"35","author":"Chuang","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13195-017-0297-z","article-title":"Alzheimer\u2019s disease prevention: from risk factors to early intervention","volume":"9","author":"Crous-Bou","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"E12050","DOI":"10.1002\/trc2.12050","article-title":"Alzheimer\u2019s disease drug development pipeline: 2020","volume":"6","author":"Cummings","year":"2020","journal-title":"Alzheimers Dement."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer\u2019s disease drug-development pipeline: few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3233\/JAD-2011-110347","article-title":"Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias","volume":"26","author":"Davies","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3389\/fphys.2012.00484","article-title":"Effects of angiotensin ii on the cerebral circulation: role of oxidative stress","volume":"3","author":"De Silva","year":"2012","journal-title":"Front. Physiol."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.vph.2006.05.002","article-title":"Molecular activation of Ppargamma by angiotensin ii type 1-receptor antagonists","volume":"45","author":"Erbe","year":"2006","journal-title":"Vasc. Pharmacol."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.1172\/JCI86950","article-title":"Perivascular macrophages mediate the neurovascular and cognitive dysfunction associated with hypertension","volume":"126","author":"Faraco","year":"2016","journal-title":"J. Clin. Invest."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1192\/bjpo.bp.116.004184","article-title":"Associations of centrally acting ace inhibitors with cognitive decline and survival in Alzheimer's disease","volume":"3","author":"Fazal","year":"2017","journal-title":"BJPsych Open"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"E22785","DOI":"10.1002\/jbt.22785","article-title":"Cardioprotective effects of Azilsartan compared with that of Telmisartan on an in vivo model of myocardial ischemia-reperfusion injury","volume":"35","author":"Garg","year":"2021","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3389\/fphar.2018.00440","article-title":"Targeting Renin-Angiotensin System Against Alzheimer's Disease","volume":"9","author":"Gebre","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/pds.3449","article-title":"Time until incident dementia among Medicare beneficiaries using centrally acting or non-centrally acting ace inhibitors","volume":"22","author":"Hebert","year":"2013","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"721858","DOI":"10.3389\/fnagi.2021.721858","article-title":"Cardiometabolic modification of amyloid Beta in Alzheimer's disease pathology","volume":"13","author":"Hefner","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.mcn.2005.03.012","article-title":"Angiotensin-(1-7) enhances Ltp in the hippocampus through the G-protein-coupled receptor mas","volume":"29","author":"Hellner","year":"2005","journal-title":"Mol. Cell. Neurosci."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"37644","DOI":"10.1074\/jbc.M508460200","article-title":"Amyloid Beta-protein is degraded by cellular angiotensin-converting enzyme (ace) and elevated by an ace inhibitor","volume":"280","author":"Hemming","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1161\/HYPERTENSIONAHA.121.17049","article-title":"Blood-brain barrier crossing renin-angiotensin drugs and cognition in the elderly: a meta-analysis","volume":"78","author":"Ho","year":"2021","journal-title":"Hypertension"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1253\/circj.CJ-12-0658","article-title":"Angiotensin-receptor blockers and risk of Alzheimer\u2019s disease in hypertension population","volume":"77","author":"Hsu","year":"2013","journal-title":"Circ. J."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/jcbfm.2011.133","article-title":"Direct stimulation of angiotensin ii type 2 receptor enhances spatial memory","volume":"32","author":"Jing","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"837890","DOI":"10.3389\/fphar.2022.837890","article-title":"Protective effect of renin-angiotensin system inhibitors on Parkinson\u2019s disease: a Nationwide cohort study","volume":"13","author":"Jo","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1097\/HJH.0b013e32834c46fd","article-title":"Molecular and cellular effects of Azilsartan: a new generation angiotensin ii receptor blocker","volume":"29","author":"Kajiya","year":"2011","journal-title":"J. Hypertens."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13195-016-0217-7","article-title":"Angiotensin-converting enzyme 2 is reduced in Alzheimer's disease in association with increasing amyloid-\u0392 and tau pathology","volume":"8","author":"Kehoe","year":"2016","journal-title":"Alzheimers Res. Ther."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"295925","DOI":"10.1155\/2015\/295925","article-title":"Effect of long-term treatment with Fimasartan on transient focal ischemia in rat brain","volume":"2015","author":"Kim","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3346\/jkms.2017.32.5.718","article-title":"Towards actualizing the value potential of Korea health insurance review and assessment (Hira) data as a resource for Health Research: strengths, limitations, applications, and strategies for optimal use of Hira data","volume":"32","author":"Kim","year":"2017","journal-title":"J. Korean Med. Sci."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/heapol\/czn037","article-title":"Thirty years of National Health Insurance in South Korea: lessons for achieving universal health care coverage","volume":"24","author":"Kwon","year":"2009","journal-title":"Health Policy Plan."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1172\/JCI41709","article-title":"Angiotensin ii sustains brain inflammation in mice via Tgf-Beta","volume":"120","author":"Lanz","year":"2010","journal-title":"J. Clin. Invest."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3233\/JAD-190474","article-title":"Midlife hypertension and Alzheimer's disease: a systematic review and meta-analysis","volume":"71","author":"Lennon","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"b5465","DOI":"10.1136\/bmj.b5465","article-title":"Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis","volume":"340","author":"Li","year":"2010","journal-title":"BMJ"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the lancet commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"10139","DOI":"10.3390\/ijms221810139","article-title":"Brain renin-angiotensin system as novel and potential therapeutic target for Alzheimer's disease","volume":"22","author":"Loera-Valencia","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"E2145319","DOI":"10.1001\/jamanetworkopen.2021.45319","article-title":"Association of Antihypertensives that stimulate vs inhibit types 2 and 4 angiotensin ii receptors with cognitive impairment","volume":"5","author":"Marcum","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1124\/pr.112.007278","article-title":"A systematic comparison of the properties of clinically used angiotensin ii type 1 receptor antagonists","volume":"65","author":"Michel","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1447-0594.2012.00900.x","article-title":"Effect of angiotensin ii type 2 receptor on stroke, cognitive impairment and neurodegenerative diseases","volume":"13","author":"Mogi","year":"2013","journal-title":"Geriatr Gerontol Int"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.bbrc.2008.08.032","article-title":"Telmisartan prevented cognitive decline partly due to Ppar-gamma activation","volume":"375","author":"Mogi","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/jcbfm.1994.143","article-title":"Angiotensin iv reverses the acute cerebral blood flow reduction after experimental subarachnoid hemorrhage in the rat","volume":"14","author":"N\u00e4veri","year":"1994","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3233\/JAD-131694","article-title":"Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer's disease","volume":"40","author":"O\u2019Caoimh","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"ref48","first-page":"266","article-title":"Interactions between Oestrogen and the renin angiotensin system\u2013potential mechanisms for gender differences in Alzheimer's disease","volume":"1","author":"O\u2019Hagan","year":"2012","journal-title":"Am. J. Neurodegener. Dis."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/j.1532-5415.2004.52178_7.x","article-title":"Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan","volume":"52","author":"Ohrui","year":"2004","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1527-3466.1988.tb00376.x","article-title":"Delapril","volume":"6","author":"Oka","year":"1988","journal-title":"Cardiovasc. Drug Rev."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13195-021-00778-8","article-title":"The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer\u2019s disease: the importance of blood-brain barrier penetration and APOE \u03b54 carrier status","volume":"13","author":"Ouk","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/HJH.0b013e32834dde5f","article-title":"Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-\u0393 activation in human monocytes","volume":"30","author":"Pang","year":"2012","journal-title":"J. Hypertens."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.biopsych.2009.02.013","article-title":"Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders","volume":"67","author":"Profenno","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jagp.2012.08.017","article-title":"Angiotensin converting enzyme inhibitors and Alzheimer disease in the presence of the apolipoprotein E4 allele","volume":"22","author":"Qiu","year":"2014","journal-title":"Am. J. Geriatr. Psychiatr."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/archneur.62.7.1047","article-title":"Statin use and the risk of incident dementia: the cardiovascular health study","volume":"62","author":"Rea","year":"2005","journal-title":"Arch. Neurol."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/jamaneurol.2016.0580","article-title":"Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively Normal older adults","volume":"73","author":"Risacher","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.neurobiolaging.2014.10.028","article-title":"Critical period for dopaminergic neuroprotection by hormonal replacement in menopausal rats","volume":"36","author":"Rodriguez-Perez","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.neurobiolaging.2009.04.008","article-title":"Brain levels of sex steroid hormones in men and women during Normal aging and in Alzheimer's disease","volume":"32","author":"Rosario","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s11357-020-00231-y","article-title":"Brain angiotensin ii and angiotensin iv receptors as potential Alzheimer's disease therapeutic targets","volume":"42","author":"Royea","year":"2020","journal-title":"Geroscience"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/archinternmed.2009.175","article-title":"Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the cardiovascular health study","volume":"169","author":"Sink","year":"2009","journal-title":"Arch. Intern. Med."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1291\/hypres.27.213","article-title":"Significant target organs for hypertension and cardiac hypertrophy by angiotensin-converting enzyme inhibitors","volume":"27","author":"Takai","year":"2004","journal-title":"Hypertens. Res."},{"key":"ref62","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1097\/EDE.0000000000001245","article-title":"Comparison of antihypertensive drug classes for dementia prevention","volume":"31","author":"Walker","year":"2020","journal-title":"Epidemiology"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1111\/jgs.13627","article-title":"Modulation of renin-angiotensin system may slow conversion from mild cognitive impairment to Alzheimer's disease","volume":"63","author":"Wharton","year":"2015","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3233\/JAD-2012-120763","article-title":"The effects of Ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial","volume":"32","author":"Wharton","year":"2012","journal-title":"J. Alzheimers Dis."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3233\/JAD-220262","article-title":"Making the case for accelerated withdrawal of Aducanumab","volume":"87","author":"Whitehouse","year":"2022","journal-title":"J. Alzheimers Dis."},{"key":"ref66","year":"2021"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3233\/JAD-181035","article-title":"Contributions by the brain renin-angiotensin system to memory, cognition, and Alzheimer's disease","volume":"67","author":"Wright","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"716917","DOI":"10.3389\/fnagi.2021.716917","article-title":"Microglial Trem2 mitigates inflammatory responses and neuronal apoptosis in angiotensin ii-induced hypertension in middle-aged mice","volume":"13","author":"Xu","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1136\/jnnp-2015-310548","article-title":"Meta-analysis of modifiable risk factors for Alzheimer's disease","volume":"86","author":"Xu","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/hr.2013.51","article-title":"Renin-angiotensin-aldosterone system has a pivotal role in cognitive impairment","volume":"36","author":"Yagi","year":"2013","journal-title":"Hypertens. Res."},{"key":"ref71","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1212\/WNL.0b013e3182a35228","article-title":"Antihypertensive drugs decrease risk of Alzheimer disease: ginkgo evaluation of memory study","volume":"81","author":"Yasar","year":"2013","journal-title":"Neurology"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.maturitas.2017.06.021","article-title":"Access to anti-osteoporosis medication after hip fracture in Korean elderly patients","volume":"103","author":"Yu","year":"2017","journal-title":"Maturitas"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"8628","DOI":"10.1523\/JNEUROSCI.1549-07.2007","article-title":"Angiotensin-converting enzyme converts amyloid Beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition","volume":"27","author":"Zou","year":"2007","journal-title":"J. Neurosci."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2023.1137197\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T06:06:14Z","timestamp":1678082774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2023.1137197\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,6]]},"references-count":73,"alternative-id":["10.3389\/fnagi.2023.1137197"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2023.1137197","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,6]]},"article-number":"1137197"}}